Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Annals of Neurology|February 21, 2013
On being a neurologist in industryDavid Leppert, Robert GlanzmanJournal of the Neurological Sciences|August 4, 2007
The role of optical coherence tomography in multiple sclerosis: expert panel consensusRobert C Sergott, Elliot Frohman, Robert Glanzman, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 3, 2012
EDSS variability before randomization may limit treatment discovery in primary progressive MSJiameng Zhang, Emmanuelle Waubant, Gary Cutter, et al.BMJ Open|January 12, 2021
Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progressionSteve Vucic, Matthew C Kiernan, Parvathi Menon, et al.Multiple Sclerosis and Related Disorders|September 21, 2016
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and designFrancois Curtin, Herve Porchet, Robert Glanzman, et al.Multiple Sclerosis and Related Disorders|June 24, 2017
Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017David Kremer, Robert Glanzman, Anthony Traboulsee, et al.Muscle & Nerve|August 11, 2021
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollmentSteve Vucic, Toby A Ferguson, Catherine Cummings, et al.Lancet (London, England)|November 4, 2011
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, David Li, Peter A Calabresi, et al.Eclinicalmedicine|July 3, 2023
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extensionSteve Vucic, Parvathi Menon, William Huynh, et al.Journal of Nanobiotechnology|December 13, 2023
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trialsJimin Ren, Richard B Dewey, Austin Rynders, et al.Pageof 2